Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30661336 | 0.85 | HSD11B1 (0.51) | CYP2D6STSCHRM1GPR119CYP1A2 | |
| SCHEMBL20765293 | 0.85 | HSD11B1 (0.51) | CYP2D6STSCHRM1GPR119CYP1A2 | |
| SCHEMBL9852971 | 0.80 | CYP2D6 (0.62) | CYP2D6ALDH1A1KDM4EKMT2APOLB | |
| SCHEMBL3951230 | 0.79 | ALDH1A1 (0.55) | CYP2D6ALDH1A1KMT2APOLBLMNA | |
| SCHEMBL3951233 | 0.79 | ALDH1A1 (0.55) | CYP2D6ALDH1A1KMT2APOLBLMNA | |
| SCHEMBL6309361 | 0.78 | CHRM1 (0.46) | CHRM1GPR119CHRM4CHRM5 | |
| SCHEMBL21647056 | 0.77 | ALDH1A1 (0.47) | CYP2D6ALDH1A1KMT2ACYP1A2POLB | |
| SCHEMBL21646967 | 0.77 | ALDH1A1 (0.47) | CYP2D6ALDH1A1KMT2ACYP1A2POLB | |
| SCHEMBL27091400 | 0.77 | ALDH1A1 (0.48) | CYP2D6ALDH1A1KMT2ACYP1A2POLB | |
| SCHEMBL1359448 | 0.76 | ALDH1A1 (0.62) | CYP2D6ALDH1A1KDM4EKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119258067-A | Substituted piperidine compounds and uses thereof | 卫材R&D管理有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-119235864-A | Substituted piperidine compounds and uses thereof | 卫材R&D管理有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-115884971-B | Substituted piperidine compounds and uses thereof | 卫材R&D管理有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-115884971-A | Substituted piperidine compounds and uses thereof | 卫材R&D管理有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-11479552-B2 | Substituted piperidine compounds and their use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479552-B2 | Substituted piperidine compounds and their use | HCRTR2, HCRTR1, NPY2R | CYP2D6 1227/4885ALDH1A1 592/4885STS 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.